Amlodipine/Atorvastatin (Caduet®) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Status:
Completed
Trial end date:
2012-04-01
Target enrollment:
Participant gender:
Summary
In this survey, to collect the safety and efficacy information of Amlodipine /Atorvastatin
(Caduet® Combination Tablets) in daily medical practice will be examined. In addition, the
necessity of special Investigation and post-marketing clinical studies will be examined,
while investigating unexpected adverse drug reactions during the survey period and
understanding of the status of frequency of adverse drug reactions in daily medical practice.
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Amlodipine Amlodipine, atorvastatin drug combination Atorvastatin Atorvastatin Calcium